Oslo, Norway 28 May 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, announces it is hosting a live update webcast at 10:00am CET today Wednesday 28 May 2025. In the webcast, Circio management will present novel in vivo data for its circular RNA expression technology. This data broadens the therapeutic development and partnership opportunities of the circVec platform.  

In the presentation, Circio´s CTO Dr. Thomas B Hansen will showcase the latest circVec DNA gene and cell therapy in vivo data. circVec continues to perform substantially better than equivalent mRNA vectors in multiple settings. In addition to increased and prolonged protein expression, a distinct tissue expression pattern is emerging, pointing to development opportunities in specific disease areas.

“It is becoming evident that circular RNA-based expression has a completely different biology compared to mRNA vectors. This creates a unique set of opportunities for Circio´s circVec platform,” said Dr. Thomas B Hansen, CTO of Circio. “Interestingly, the increased and prolonged expression level is more pronounced in certain tissues, and absent in others, which gives us clear targets to proceed with. Muscle, heart and spleen have emerged as sites where circVec is particularly advantageous. As a result, we have identified several potential development opportunities in muscle and cardiac genetic disease, which are not well served by conventional approaches.”

Substantial progress has been made on circVec-AAV gene therapy development. Mice have been monitored for up to six months following one systemic administration, showing a 50% increase in total expression level vs. mRNA-AAV. Importantly, post mortem ex vivo tissue and organ analysis after six months reveal a unique signal distribution. Circio is in the process of exploring these observations in further detail, and early data indicate 10-fold increased potency for circVec-AAVs designed for specific expression in heart.   

“The heart AAV data indicating up to a 10-fold increase in potency for circVec is precisely what we have been working towards achieving,” said Dr. Erik D Wiklund, CEO of Circio. “Our latest data package points to a strong advantage for circVec in tissue-specific AAV gene therapy and DNA-format in vivo cell therapy. Following broad interest at the recent ASGCT 2025 conference, Circio is in the process of discussing the latest results with experts in these fields and aim to continue development both in house and through partnerships. This will allow us to generate external validation of the circVec technology and accelerate platform development towards defining Circio´s first therapeutic candidates.”

In the webcast, CEO Dr Erik D Wiklund will also provide a corporate update, and discuss the upcoming annual general meeting on 5 June 2025.

Presenters:
CEO Dr. Erik Digman Wiklund 
CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CEST on 28 May 2025

Click here to access Teams webcast
Meeting ID: 391 953 079 039 3
Passcode: PB2gk7wt

Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast

A recording of the webcast will be made available on the Circio webpage